April 26, 2025 02:00 PM EDT

J&J reports durability data for bladder cancer 'pretzel' drug after FDA filing

Ayisha Sharma

News Reporter

Johnson & Johnson said its drug-device combo for bladder cancer achieved a high rate of complete responses lasting at least a year, according to the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

J&J reports durability data for bladder cancer 'pretzel' drug after FDA filing

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

New fund will pressure flailing biotechs, as investor frustration boils over

Akeso shares new data suggesting it can beat Keytruda on survival, wins China approval

FDA chief Makary talks expediting drug approvals, RIFs and the abortion pill

AbbVie commits $10B to expand US footprint with the threat of tariffs ahead

Paul Stoffels on retiring from Galapagos; Boehringer Ingelheim switches up leadership

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

J&J re­ports dura­bil­i­ty da­ta for blad­der can­cer 'pret­zel' drug af­ter FDA fil­ing

News Reporter

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

J&J reports durability data for bladder cancer 'pretzel' drug after FDA filing